MAIA Biotechnology (MAIA) Interest & Investment Income (2021 - 2025)
MAIA Biotechnology (MAIA) posted quarterly Interest & Investment Income of $79697.0 for Q2 2025, down 9.83% year-over-year from $88383.0 in Q2 2024, and down 3.02% quarter-over-quarter from $82183.0 in Q1 2025.
MAIA Biotechnology (MAIA) Interest & Investment Income (2021 - 2025) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Interest & Investment Income for 5 consecutive years, with $79697.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Interest & Investment Income fell 9.83% year-over-year to $79697.0; the TTM figure through Jun 2025 stood at $347746.0 (up 108.88% YoY), while the FY2024 annual figure was $318367.0, up 823.07% from the prior year.
- Interest & Investment Income declined to $79697.0 in Q2 2025 per MAIA's latest filing, from $82183.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $106082.0 in Q3 2024 and bottomed at $172.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $30498.7 across 5 years, with a median of $708.0 in 2021.
- Annual changes were most pronounced in 2023 — Interest & Investment Income tumbled 59.91% — and 2024, when it surged 51285.47%.
- MAIA Biotechnology's Interest & Investment Income stood at $511.0 in 2021, then advanced by 21.53% to $621.0 in 2022, then jumped by 4847.18% to $30722.0 in 2023, then soared by 159.7% to $79784.0 in 2024, then fell by 0.11% to $79697.0 in 2025.
- Business Quant data shows MAIA's Interest & Investment Income at $79697.0 in Q2 2025, $82183.0 in Q1 2025, and $79784.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 79,697.00 |
| Mar 31, 2025 | 82,183.00 |
| Dec 31, 2024 | 79,784.00 |
| Sep 30, 2024 | 106,082.00 |
| Jun 30, 2024 | 88,383.00 |
| Mar 31, 2024 | 44,118.00 |
| Dec 31, 2023 | 30,722.00 |
| Sep 30, 2023 | 3,260.00 |
| Jun 30, 2023 | 172.00 |
| Mar 31, 2023 | 336.00 |
| Dec 31, 2022 | 621.00 |
| Sep 30, 2022 | 348.00 |
| Jun 30, 2022 | 429.00 |
| Mar 31, 2022 | 472.00 |
| Dec 31, 2021 | 511.00 |
| Sep 30, 2021 | 708.00 |
| Jun 30, 2021 | 652.00 |